Statements (55)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:hospital
|
| gptkbp:available_sizes |
multiple diameters and lengths
|
| gptkbp:clinical_trial |
conducted for efficacy
SPIRIT trials in various cardiac procedures ongoing to assess new indications |
| gptkbp:coat_of_arms |
gptkb:everolimus
|
| gptkbp:collaborations |
with academic institutions
|
| gptkbp:competes_with |
other drug-eluting stents
|
| gptkbp:delivers |
balloon catheter
|
| gptkbp:design |
thin strut design
|
| gptkbp:education |
important for informed consent
|
| gptkbp:effective_date |
gptkb:2012
|
| gptkbp:features |
biocompatible polymer
|
| gptkbp:feedback |
collected for product development
|
| gptkbp:healthcare |
received in 2012
|
| https://www.w3.org/2000/01/rdf-schema#label |
Xience Xpedition
|
| gptkbp:indication |
percutaneous coronary intervention
|
| gptkbp:innovation |
in stent technology
|
| gptkbp:is_designed_to |
to prevent restenosis
|
| gptkbp:is_effective_against |
supported by evidence
|
| gptkbp:is_used_for |
treating coronary artery disease
|
| gptkbp:lifespan |
includes updates and improvements
|
| gptkbp:manufacturer |
gptkb:Abbott_Laboratories
|
| gptkbp:market |
conducted regularly
|
| gptkbp:market_segment |
interventional cardiology
|
| gptkbp:marketed_as |
multiple countries
|
| gptkbp:marketing_strategy |
focused on cardiologists
|
| gptkbp:part_of |
Xience family of stents
|
| gptkbp:partnerships |
with healthcare providers
|
| gptkbp:population |
varied by region
adults with coronary artery disease |
| gptkbp:price |
varies by region
|
| gptkbp:provides_information_on |
included in treatment protocols
|
| gptkbp:reach |
available in many markets worldwide
|
| gptkbp:receives_funding_from |
available in many healthcare systems
|
| gptkbp:recruitment |
criteria established for use
|
| gptkbp:reduces |
restenosis rates
|
| gptkbp:regulatory_compliance |
approved for use
|
| gptkbp:research |
show long-term safety
|
| gptkbp:research_focus |
long-term outcomes
|
| gptkbp:risk_factor |
thrombosis
|
| gptkbp:safety_features |
generally favorable
|
| gptkbp:shipping_options |
percutaneous approach
|
| gptkbp:side_effect |
monitored in studies
significant in interventional cardiology. |
| gptkbp:stations |
enhanced visibility
|
| gptkbp:supply_chain |
managed by Abbott Laboratories
|
| gptkbp:training |
required for use
|
| gptkbp:treatment |
tracked in registries
improved compared to bare-metal stents |
| gptkbp:type |
gptkb:musician
|
| gptkbp:was_marked_by |
obtained in Europe
|
| gptkbp:bfsParent |
gptkb:Xience_drug-eluting_stent
|
| gptkbp:bfsLayer |
7
|